Daratumumab for the treatment of refractory ANCA-associated vasculitis | RMD Open

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest Content

Archive

For authors

About

Podcasts
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Vasculitis

Short report

Daratumumab for the treatment of refractory ANCA-associated vasculitis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Ostendorf L, Burns M, Wagner DL, et al

Daratumumab for the treatment of refractory ANCA-associated vasculitis

RMD Open 2023;9:e002742. doi: 10.1136/rmdopen-2022-002742